Versant Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $20.8K | Hold |
1,424
| – | – | ﹤0.01% | 1903 |
|
|
2026
Q1 | $18K | Hold |
1,424
| – | – | ﹤0.01% | 1869 |
|
|
2025
Q4 | $22.5K | Hold |
1,424
| – | – | ﹤0.01% | 1566 |
|
|
2025
Q3 | $17K | Hold |
1,424
| – | – | ﹤0.01% | 1676 |
|
|
2025
Q2 | $10.8K | Buy |
+1,424
| New | +$8.57K | ﹤0.01% | 1863 |
|
|
2024
Q4 | – | Sell |
-87
| Closed | -$901 | – | 2391 |
|
|
2024
Q3 | $901 | Buy |
87
+36
| +71% | +$471 | ﹤0.01% | 1773 |
|
|
2024
Q2 | $661 | Sell |
51
-18
| -26% | -$243 | ﹤0.01% | 1741 |
|
|
2024
Q1 | $1.21K | Hold |
69
| – | – | ﹤0.01% | 1493 |
|
|
2023
Q4 | $649 | Buy |
69
+20
| +41% | +$186 | ﹤0.01% | 1621 |
|
|
2023
Q3 | $547 | Sell |
49
-514
| -91% | -$8.28K | ﹤0.01% | 1673 |
|
|
2023
Q2 | $12K | Buy |
563
+458
| +436% | +$13.5K | ﹤0.01% | 703 |
|
|
2023
Q1 | $4.23K | Sell |
105
-7
| -6% | -$334 | ﹤0.01% | 1004 |
|
|
2022
Q4 | $5.21K | Sell |
112
-31
| -22% | -$1.41K | ﹤0.01% | 881 |
|
|
2022
Q3 | $7K | Buy |
143
+39
| +38% | +$2.28K | ﹤0.01% | 743 |
|
|
2022
Q2 | $5K | Hold |
104
| – | – | ﹤0.01% | 850 |
|
|
2022
Q1 | $7K | Sell |
104
-41
| -28% | -$2.67K | ﹤0.01% | 777 |
|
|
2021
Q4 | $11K | Hold |
145
| – | – | ﹤0.01% | 687 |
|
|
2021
Q3 | $8K | Buy |
145
+84
| +138% | +$4.15K | ﹤0.01% | 751 |
|
|
2021
Q2 | $3K | Buy |
61
+4
| +7% | +$196 | ﹤0.01% | 1033 |
|
|
2021
Q1 | $3K | Buy |
+57
| New | +$2.84K | ﹤0.01% | 1145 |
|
|
2020
Q2 | – | Sell |
-23
| Closed | -$1K | – | 1360 |
|
|
2020
Q1 | $1K | Hold |
23
| – | – | ﹤0.01% | 1128 |
|
|
2019
Q4 | $1K | Hold |
23
| – | – | ﹤0.01% | 1221 |
|
|
2019
Q3 | $1K | Hold |
23
| – | – | ﹤0.01% | 1240 |
|
|
2019
Q2 | $1K | Sell |
23
-41
| -64% | -$3.69K | ﹤0.01% | 1271 |
|
|
2019
Q1 | $6K | Sell |
64
-19
| -23% | -$1.7K | ﹤0.01% | 1045 |
|
|
2018
Q4 | $5K | Hold |
83
| – | – | ﹤0.01% | 1016 |
|
|
2018
Q3 | $7K | Hold |
83
| – | – | ﹤0.01% | 982 |
|
|
2018
Q2 | $9K | Hold |
83
| – | – | ﹤0.01% | 916 |
|
|
2018
Q1 | $6K | Hold |
83
| – | – | ﹤0.01% | 1019 |
|
|
2017
Q4 | $4K | Hold |
83
| – | – | ﹤0.01% | 1166 |
|
|
2017
Q3 | $3K | Sell |
83
-76
| -48% | -$3.06K | ﹤0.01% | 1157 |
|
|
2017
Q2 | $5K | Sell |
159
-11
| -6% | -$352 | ﹤0.01% | 1046 |
|
|
2017
Q1 | $5K | Sell |
170
-3
| -2% | -$93 | ﹤0.01% | 1038 |
|
|
2016
Q4 | $5K | Hold |
173
| – | – | ﹤0.01% | 1012 |
|
|
2016
Q3 | $4K | Buy |
173
+157
| +981% | +$3.65K | ﹤0.01% | 1035 |
|
|
2016
Q2 | $0 | Sell |
16
-138
| -90% | -$3.61K | ﹤0.01% | 1362 |
|
|
2016
Q1 | $4K | Buy |
154
+115
| +295% | +$3.2K | ﹤0.01% | 991 |
|
|
2015
Q4 | $1K | Buy |
+39
| New | +$1.27K | ﹤0.01% | 1223 |
|
Other funds holding ENTA
GI
TWD
FFA
TM
Versant Capital Management's ENTA Position: Q2 2026 in Review
Versant Capital Management held its Enanta Pharmaceuticals (ENTA) position steady in Q2 2026 at 1,424 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1903.
Versant Capital Management first reported a position in ENTA in Q4 2015 and has held it in 38 quarters since. The position peaked at $22.5K in Q4 2025. 6 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.
- Versant Capital Management held 1,424 shares of Enanta Pharmaceuticals worth $20.8K as of Q2 2026.
- Versant Capital Management left its Enanta Pharmaceuticals share count unchanged in Q2 2026.
- Enanta Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1903 holding.
- Versant Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2015 and has held it in 38 quarters since.
- Versant Capital Management's Enanta Pharmaceuticals position peaked at $22.5K in Q4 2025.
- 6 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.